Local view for "http://purl.org/linkedpolitics/eu/plenary/2010-11-23-Speech-2-221"

Predicate	Value (sorted: default)
rdf:type	lpv_eu:Speech2
dcterms:Date	"2010-11-23"^^xsd:date2
dcterms:Is Part Of	lp_eu:Explanations of vote2
dcterms:Language	"pt"^^xsd:language2
lpv:document identification number	"en.20101123.33.2-221"2
lpv:hasSubsequent	lp_eu:2010-11-23-Speech-2-9372
lpv:speaker	lp:Diogo Feio2
lpv:spokenAs	substitute; Delegation to the ACP-EU Joint Parliamentary Assembly (2009-09-16--2014-06-30)3 unknown; Partido Popular (2009-07-14--2014-06-30)3 member; Delegation to the EU-Kazakhstan, EU-Kyrgyzstan and EU-Uzbekistan Parliamentary Cooperation Committees, and for relations with Tajikistan, Turkmenistan and Mongolia (2009-09-16--2014-06-30)3 member; ECON (2009-07-16--2012-01-18)3 member; EPP (2009-07-14--2014-06-30)3 substitute; AFET (2009-07-16--2012-01-18)3 substitute; Special Committee on the Financial, Economic and Social Crisis (2009-10-08--2011-07-31)3
lpv:translated text	"Given the importance of the pharmaceuticals trade, not just to public health but also to the economy, I welcome the decision to include 718 new substances on the list of products eligible for duty-free treatment. The arrangement is unanimously supported by the pharmaceutical industry because it eliminates tariffs on inputs and intermediaries that have to be paid even in connection with intra-company trade, thereby facilitating international trade in these products and benefiting pharmaceutical companies. This arrangement could, in the final analysis, be reflected in the retail price of medicines sold to the public."@en1

Named graphs describing this resource:

The resource appears as object in 2 triples

Context graph